Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Bayer and Lion Bioscience look for new drugs, diagnostics

22 Feb 2000

Executive Summary

Bayer will collaborate with Heidelberg-based Lion Bioscience (sequencing and biocomputing services) in a five-year research agreement. Bayer will make precommmercial payments totaling up to $50-60mm, including an up-front equity investment, technology access fees, R&D money (estimated at $25-30mm), and set-up funds for a new subsidiary named Lion Bioscience Research Inc.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Joint Venture

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By